… ProQR update and additional sepofarsen Illuminate trial … and restructuring initiatives: Focus the ultevursen (QR-421a) program for USH2A -mediated Usher syndrome and … with regulatory authorities. Suspend development of QR-1123 for autosomal dominant retinitis pigmentosa and QR-504a …
